Open-label RCT in China, rifampicin-resistant pulmonary TB: a 6- to 9-month all-oral regimen was non-inferior to a 9-month injectable-containing regimen (favourable outcome at 84 weeks 76.1% vs 63.7%; 312 of 354 analysed). Grade 3-5 AEs 59.5% vs 69.1%.
RCTn = 354
Sun et al. A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China